New Frontiers in Breast Cancer Research, Part I: Advances in Imaging and Diagnosis
After years of working for a "cure" for breast cancer, researchers have come to realize the enormity of the task. Although therapeutic advances are making it possible for women with advanced breast cancer to live longer, more comfortable lives, scientists still have a long way to go before they fully understand this complex disease. At this year's Society of Surgical Oncology's annual Cancer Symposium, researchers zeroed in on several key areas that could eventually unlock new methods of controlling, and possibly eliminating, this all too pervasive threat.
by Kristina Rebelo and Mary Thompson
Breast cancer is expected to strike more than 192,000 American
women this year and over 40,000 will die of the disease, according
to the latest data from the American Cancer Society (ACS). (See
Exhibit 1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.
